Caitlin C Murphy1, Linda C Harlan2, Jennifer L Lund2, Charles F Lynch2, Ann M Geiger2. 1. Affiliations: Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC (CCM, JLL); Healthcare Delivery Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, Rockville, MD (LCH, AMG); Department of Epidemiology, University of Iowa, Iowa City, IA (CFL). caitlin_murphy@med.unc.edu. 2. Affiliations: Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC (CCM, JLL); Healthcare Delivery Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, Rockville, MD (LCH, AMG); Department of Epidemiology, University of Iowa, Iowa City, IA (CFL).
Abstract
BACKGROUND: Colorectal cancer (CRC) mortality has declined in the United States, in part because of advances in treatment. Few studies have evaluated the adoption of therapies and temporal changes in patterns of care. METHODS: Patients age 20 years and older diagnosed with stages II/III CRC were randomly sampled from the population-based Surveillance, Epidemiology, and End Results (SEER) program in 1990-1991, 1995, 2000, 2005, and 2010 (n = 7057). Therapy was obtained from medical records and physician verification. We described the receipt of chemotherapy and radiation therapy. Log-binomial regression was used to examine factors associated with therapy. All statistical tests were two-sided. RESULTS: Chemotherapy receipt among colon cancer patients increased from 1990 (stage II: 22.5%; stage III: 56.3%) to 2005 (stage II: 32.1%; stage III: 72.4%) and declined slightly in 2010 (stage II: 29.3%; stage III: 66.4%). Stage III colon cancer patients who were older (vs <55 years, 75-79 years: risk ratio [RR] 0.81, 95% confidence interval [CI] = 0.71 to 0.91; ≥80 years: RR = 0.37, 95% CI = 0.28 to 0.47) or had a comorbidity score of 2 or higher (vs 0, RR = 0.56, 95% CI = 0.35 to 0.87) received chemotherapy less often. Receipt of radiation therapy by rectal cancer patients increased across all years from 45.5% to 66.1%. Increasing age (vs <55 years, 75-79 years: RR = 0.59, 95% CI = 0.47 to 0.74; ≥80 years: RR = 0.33, 95% CI = 0.25 to 0.45) was associated with lower chemoradiation use among stage II/III rectal cancer patients. CONCLUSION: Our findings demonstrate increased adoption of chemotherapy and radiation therapy for colon and rectal cancer patients and differences in therapy by age, comorbidity, and diagnosis year. Increased receipt of these therapies in the community may further reduce CRC mortality.
BACKGROUND:Colorectal cancer (CRC) mortality has declined in the United States, in part because of advances in treatment. Few studies have evaluated the adoption of therapies and temporal changes in patterns of care. METHODS:Patients age 20 years and older diagnosed with stages II/III CRC were randomly sampled from the population-based Surveillance, Epidemiology, and End Results (SEER) program in 1990-1991, 1995, 2000, 2005, and 2010 (n = 7057). Therapy was obtained from medical records and physician verification. We described the receipt of chemotherapy and radiation therapy. Log-binomial regression was used to examine factors associated with therapy. All statistical tests were two-sided. RESULTS: Chemotherapy receipt among colon cancerpatients increased from 1990 (stage II: 22.5%; stage III: 56.3%) to 2005 (stage II: 32.1%; stage III: 72.4%) and declined slightly in 2010 (stage II: 29.3%; stage III: 66.4%). Stage III colon cancerpatients who were older (vs <55 years, 75-79 years: risk ratio [RR] 0.81, 95% confidence interval [CI] = 0.71 to 0.91; ≥80 years: RR = 0.37, 95% CI = 0.28 to 0.47) or had a comorbidity score of 2 or higher (vs 0, RR = 0.56, 95% CI = 0.35 to 0.87) received chemotherapy less often. Receipt of radiation therapy by rectal cancerpatients increased across all years from 45.5% to 66.1%. Increasing age (vs <55 years, 75-79 years: RR = 0.59, 95% CI = 0.47 to 0.74; ≥80 years: RR = 0.33, 95% CI = 0.25 to 0.45) was associated with lower chemoradiation use among stage II/III rectal cancerpatients. CONCLUSION: Our findings demonstrate increased adoption of chemotherapy and radiation therapy for colon and rectal cancerpatients and differences in therapy by age, comorbidity, and diagnosis year. Increased receipt of these therapies in the community may further reduce CRC mortality.
Authors: Paul F Engstrom; Al B Benson; Yi-Jen Chen; Michael A Choti; Raza A Dilawari; Charles A Enke; Marwan G Fakih; Charles Fuchs; Krystyna Kiel; James A Knol; Lucille A Leong; Kirk A Ludwig; Edward W Martin; Sujata Rao; M Wasif Saif; Leonard Saltz; John M Skibber; Alan P Venook; Timothy J Yeatman Journal: J Natl Compr Canc Netw Date: 2005-07 Impact factor: 11.908
Authors: Deirdre P Cronin; Linda C Harlan; Arnold L Potosky; Limin X Clegg; Jennifer L Stevens; Margaret M Mooney Journal: Am J Gastroenterol Date: 2006-10 Impact factor: 10.864
Authors: Daniel G Haller; Paul J Catalano; John S Macdonald; Mark A O'Rourke; Michael S Frontiera; Don V Jackson; Robert J Mayer Journal: J Clin Oncol Date: 2005-12-01 Impact factor: 44.544
Authors: Chris Twelves; Alfred Wong; Marek P Nowacki; Markus Abt; Howard Burris; Alfredo Carrato; Jim Cassidy; Andrés Cervantes; Jan Fagerberg; Vassilis Georgoulias; Fares Husseini; Duncan Jodrell; Piotr Koralewski; Hendrik Kröning; Jean Maroun; Norbert Marschner; Joseph McKendrick; Marek Pawlicki; Riccardo Rosso; Johannes Schüller; Jean-François Seitz; Borut Stabuc; Jerzy Tujakowski; Guy Van Hazel; Jerzy Zaluski; Werner Scheithauer Journal: N Engl J Med Date: 2005-06-30 Impact factor: 91.245
Authors: Alfred I Neugut; Matthew Matasar; Xiaoyan Wang; Russell McBride; Judith S Jacobson; Wei-Yann Tsai; Victor R Grann; Dawn L Hershman Journal: J Clin Oncol Date: 2006-04-17 Impact factor: 44.544
Authors: Jonathan M Kocarnik; Andrew T Chan; Martha L Slattery; John D Potter; Jeffrey Meyerhardt; Amanda Phipps; Hongmei Nan; Tabitha Harrison; Thomas E Rohan; Lihong Qi; Lifang Hou; Bette Caan; Candyce H Kroenke; Howard Strickler; Richard B Hayes; Robert E Schoen; Dawn Q Chong; Emily White; Sonja I Berndt; Ulrike Peters; Polly A Newcomb Journal: Int J Cancer Date: 2016-05-14 Impact factor: 7.396
Authors: Caitlin C Murphy; Hanna K Sanoff; Karyn B Stitzenberg; John A Baron; Jennifer L Lund; Robert S Sandler Journal: J Cancer Epidemiol Date: 2017-01-23
Authors: Natalia Kunst; Fernando Alarid-Escudero; Eline Aas; Veerle M H Coupé; Deborah Schrag; Karen M Kuntz Journal: Cancer Epidemiol Biomarkers Prev Date: 2020-09-30 Impact factor: 4.254
Authors: Sandi L Pruitt; David E Gerber; Hong Zhu; Daniel F Heitjan; Bhumika Maddineni; Danyi Xiong; Amit G Singal; Anna Tavakkoli; Ethan A Halm; Caitlin C Murphy Journal: Cancer Med Date: 2021-06-30 Impact factor: 4.452